Last reviewed · How we verify

NCT04320628

Randomized Double-Blind Controlled Clinical Trial

Completed NA Last updated 14 March 2022
What this trial tests

NA trial testing AnaSept® in Chronic Wounds in 25 participants. Completed in 1 March 2022.

Timeline
20 May 2020
Primary endpoint
1 February 2022
1 March 2022

Quick facts

Lead sponsorSerenaGroup, Inc.
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment25
Start date20 May 2020
Primary completion1 February 2022
Estimated completion1 March 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

SerenaGroup, Inc. — full company profile →

Who can join

Adults 18 to 100, any sex, with Chronic Wounds or Acute Wounds. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a randomized double-blind controlled clinical trial designed to compare the ability of NaOCl to NSS in the reduction of bacterial burden in nonhealing acute and chronic wounds.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Wounds

Currently open trials in the same condition.

Other SerenaGroup, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04320628.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing